Rezaee M, Mohammadi F, Keshavarzmotamed A, Yahyazadeh S, Vakili O, Eshaghi Milasi Y
Front Pharmacol. 2023; 14:1152672.
PMID: 37153758
PMC: 10154547.
DOI: 10.3389/fphar.2023.1152672.
Zhao K, Wang X, Xue X, Li L, Hu Y
PLoS Biol. 2020; 18(3):e3000666.
PMID: 32203529
PMC: 7138317.
DOI: 10.1371/journal.pbio.3000666.
Wang X, Li L, Zhao K, Lin Q, Li H, Xue X
Cell Death Differ. 2019; 27(4):1431-1446.
PMID: 31700144
PMC: 7205893.
DOI: 10.1038/s41418-019-0449-8.
Zhu Y, Chen P, Gao Y, Ta N, Zhang Y, Cai J
EBioMedicine. 2018; 30:148-157.
PMID: 29628342
PMC: 5952405.
DOI: 10.1016/j.ebiom.2018.03.032.
Cao X, Zhuang S, Hu Y, Xi L, Deng L, Sheng H
Oncotarget. 2016; 7(14):19054-9.
PMID: 26934323
PMC: 4951351.
DOI: 10.18632/oncotarget.7764.
miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity.
OBrien K, Lowry M, Corcoran C, Martinez V, Daly M, Rani S
Oncotarget. 2015; 6(32):32774-89.
PMID: 26416415
PMC: 4741729.
DOI: 10.18632/oncotarget.5192.
Small nucleolar RNA 113-1 suppresses tumorigenesis in hepatocellular carcinoma.
Xu G, Yang F, Ding C, Zhao L, Ren H, Zhao P
Mol Cancer. 2014; 13:216.
PMID: 25217841
PMC: 4169825.
DOI: 10.1186/1476-4598-13-216.
Epigenetic silencing of genes and microRNAs within the imprinted Dlk1-Dio3 region at human chromosome 14.32 in giant cell tumor of bone.
Lehner B, Kunz P, Saehr H, Fellenberg J
BMC Cancer. 2014; 14:495.
PMID: 25005035
PMC: 4101709.
DOI: 10.1186/1471-2407-14-495.
Expression of the long non-coding RNAs MEG3, HOTAIR, and MALAT-1 in non-functioning pituitary adenomas and their relationship to tumor behavior.
Li Z, Li C, Liu C, Yu S, Zhang Y
Pituitary. 2014; 18(1):42-7.
PMID: 24469926
DOI: 10.1007/s11102-014-0554-0.
MEG3 noncoding RNA: a tumor suppressor.
Zhou Y, Zhang X, Klibanski A
J Mol Endocrinol. 2012; 48(3):R45-53.
PMID: 22393162
PMC: 3738193.
DOI: 10.1530/JME-12-0008.
Iodothyronine deiodinases and cancer.
Piekielko-Witkowska A, Nauman A
J Endocrinol Invest. 2011; 34(9):716-28.
PMID: 21623154
DOI: 10.3275/7754.
DICER1 and PRKRA in Colon Adenocarcinoma.
Chiosea S, Acquafondata M, Luo J, Kuan S, Seethala R
Biomark Insights. 2009; 3:253-258.
PMID: 19578509
PMC: 2688376.
DOI: 10.4137/bmi.s600.
MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer.
Lowery A, Miller N, Devaney A, McNeill R, Davoren P, Lemetre C
Breast Cancer Res. 2009; 11(3):R27.
PMID: 19432961
PMC: 2716495.
DOI: 10.1186/bcr2257.
Loss of heterozygosity at chromosome 14q is associated with poor prognosis in head and neck squamous cell carcinomas.
Pehlivan D, Gunduz E, Gunduz M, Nagatsuka H, Beder L, Cengiz B
J Cancer Res Clin Oncol. 2008; 134(12):1267-76.
PMID: 18521630
DOI: 10.1007/s00432-008-0423-1.
Allelic losses at genomic instability-associated loci in villous adenomas and adjacent colorectal cancers.
Brenner B, Stoler D, Rodriguez L, Karpenko M, Swede H, Petrelli N
Cancer Genet Cytogenet. 2007; 174(1):9-15.
PMID: 17350461
PMC: 1855249.
DOI: 10.1016/j.cancergencyto.2006.11.001.
Metastatic recurrence of early-stage colorectal cancer is linked to loss of heterozygosity on chromosomes 4 and 14q.
Al-Mulla F, Alfadhli S, Al-Hakim A, Going J, Bitar M
J Clin Pathol. 2006; 59(6):624-30.
PMID: 16731603
PMC: 1860407.
DOI: 10.1136/jcp.2005.033167.
Allelic loss of 14q32 in the pathogenesis of gastrointestinal and ampullary malignancies: mapping of the target region to a 17 cM interval.
Dai Y, Ho C, Tsai Y, Hsu Y, Chang Y, Liu H
J Cancer Res Clin Oncol. 2004; 131(2):94-100.
PMID: 15503134
DOI: 10.1007/s00432-004-0622-3.
Current status of human chromosome 14.
Kamnasaran D, Cox D
J Med Genet. 2002; 39(2):81-90.
PMID: 11836355
PMC: 1735028.
DOI: 10.1136/jmg.39.2.81.